Abstract It is hypothesized that insulin resistance and related metabolic factors may influence breast cancer risk, however the epidemiological evidence remains inconclusive. We conducted a case-control study nested in a prospective cohort in Northern Sweden, to clarify the associations of body mass index (BMI), leptin, adiponectin, C-peptide, and glycated haemoglobin (HbA1c) with breast cancer risk. We also investigated whether these associations may be modified by age at diagnosis, tumour stage, and oestrogen and progesterone receptor status. During follow-up, 561 women developed invasive breast cancer and 561 matched controls were selected. Conditional logistic regression was used to calculate odds ratios (OR) as estimates of relative risk, and 95% confidence intervals (CI). The associations of BMI, leptin and HbA1c with breast cancer risk differed significantly according to whether the tumour was diagnosed as stage I or stage II-IV (P heterogeneity all \0.05). These factors were significantly inversely associated with risk in the group of stage I tumours, with ORs for top vs. bottom tertile for BMI of 0.48 (95% CI, 0.30-0.78, P trend = 0.004); leptin, 0.64 (95% CI, 0.41-1.00, P trend = 0.06); and HbA1c, 0.47 (95% CI, 0.28-0.80, P trend = 0.005). For stage II-IV tumours, there was a suggestion of an increased risk with higher levels of these factors. There were no significant differences in the associations of BMI, leptin, adiponectin, C-peptide and HbA1c with breast cancer risk in subgroups of age at diagnosis or tumour receptor status. This prospective study suggests that BMI, leptin and HbA1c influence breast tumour initiation and progression.
association may differ by the oestrogen and progesterone receptor (ER/PR) status of the tumours [2, 3] and may be particularly relevant to advanced disease and cancer progression [4] . The exact mechanisms responsible for the complexity of the effect of obesity on breast cancer risk remain unknown. Obesity has effects on a number of hormones and growth factors potentially linked to breast cancer. A major cluster of obesity-related metabolic consequences include altered concentrations of circulating adipocytokines, and development of insulin resistance including hyperinsulinaemia and impaired glucose metabolism [5] . Studies examining these factors could have a substantial public health impact as many of these factors are modifiable. In addition, estimating these associations in different population or tumour subgroups may clarify the aetiological role of these factors and identify susceptible periods of tumour development. However, so far, relatively few prospective epidemiological studies have examined how these different metabolic components may be related to breast cancer risk and tumour progression, and the results have been largely inconclusive.
The aim of this prospective study, nested within The Northern Sweden Health and Disease Cohort, was to clarify the associations of factors related to overweight and insulin resistance, including body mass index (BMI), leptin, adiponectin, C-peptide and glycated haemoglobin (HbA1c) with breast cancer risk. We also investigated whether these associations may be modified by age at diagnosis, ER/PR status of the tumour, and tumour stage.
Material and methods

The study cohort
The Northern Sweden Health and Disease Cohort consists of three subcohorts; the Västerbotten Intervention Project (VIP), the Northern Sweden WHO Monitoring of Trends of Cardiovascular disease study (MONICA) and the Mammography Screening Project (MSP). The present study was based on participants in the VIP and the MSP.
The VIP is an ongoing project since 1985, to which all residents of Västerbotten county are invited to a health survey at the age of 40, 50 and 60 years; between 1985-1996, residents were also invited at the age of 30. About 59% of invited persons take part in the health survey and participants have been shown to have similar socioeconomic status as the background population [6] . Instructions before the health survey are to fast for a minimum of 8 h (4 h before 1992) and to avoid physical activity, smoking and snuffing during the last hours prior to the survey. In the present study, 95% of subjects from the VIP had fasted for 4 h or more before the health examination. The survey includes measurements of height and weight, and a blood draw. The health survey also includes a questionnaire, including questions on social life, lifestyle and medication.
The MSP has been ongoing since 1995. All women residing in Västerbotten county and who are 50-69 years old are invited every second year for breast cancer screening with mammography. Participants of the MSP are asked to donate blood for future research. Fasting before the examination is not required but fasting time since last meal is recorded; 95% of subjects from the MSP in the current study had fasted for less than 4 h. The screening examination includes a questionnaire on height, weight, menstruation, reproductive history, a brief question on family history of cancer if known, and on medication use. Since September 1998, height and weight is measured in the MSP. For subjects from the MSP, we used the best data available for height and weight; (1) from measurements at baseline (83 subjects), (2) from questionnaires (561 subjects) and (3) from the closest date (B8 years) with measured or selfreported data from another examination in the MSP or the VIP (37 subjects). Information on hormone replacement therapy (HRT) use was obtained from an open question in the questionnaire on medication use, and number of births and age at first delivery were obtained through a linkage with the birth registry, and, in the MSP cohort, also through questionnaires.
For participants of the VIP and the MSP who have given permission for use of their blood samples in research, blood samples are fractioned into plasma, buffy coat and erythrocyte aliquots and cryopreserved at -80°C. In September 2005, blood had been collected from 36,711 participants in the VIP and from 27,787 participants in the MSP. If a subject had participated in both the VIP and MSP cohort, data and plasma from the MSP were used for this study. The present study was approved by the research ethics committee of Umeå University Hospital.
Case and control selection
In September 2005, subjects who had donated blood to the VIP or to the MSP were linked to the regional cancer register, covering more than 99% of breast cancer diagnoses. A total of 757 women were found to have been diagnosed with invasive breast cancer (ICD7 170) after baseline measurement and without any other cancer diagnosis (except non-melanoma skin). Of these women, the following were excluded: 108 cases from the screening cohort due to a time to diagnosis less than 6 months after baseline, 24 cases whose blood samples were restricted for use in another study, and 64 cases due to small remaining volume in stored samples. The current study thus included 561 breast cancer cases, of which 211 were from the VIP and 350 from the MSP.
Information on tumour characteristics was extracted from medical records, pathology reports and the cancer registry, and cause of death was obtained from the National cause of death register. Oestrogen and progesterone receptor-positive tumours were defined as C0.1 fmol receptor/lg DNA.
For each case, one control without any cancer diagnosis (except non-melanoma skin cancer) at the date of diagnosis for the index case was randomly selected from the same subcohort. Case-control sets were matched for age at baseline (±6 months) and date at blood sampling (±2 months). In a few cases, the matching criteria were broadened for baseline age to ±9 months and for date at blood sampling to ±6 months.
Biochemical analyses
Plasma levels of leptin, adiponectin and C-peptide were measured at the Department of Medical Biosciences, Clinical Chemistry, Umeå University. Leptin and adiponectin levels were determined by radioimmunoassay with reagents from Linco Research (Missouri, USA) and Cpeptide concentrations were measured by radioimmunoassay, using reagents from Diagnostic Systems Laboratories (Webster, USA). Total coefficients of variation (CV) were for leptin 4.5% at 3.8 ng/ml and 5.5% at 23.6 ng/ml; for adiponectin 5.9% at 19.0 lg/ml and 9.1% at 75.0 lg/ml; and for C-peptide 7.3% at 0.5 ng/ml and 3.9% at 5.9 ng/ml. HbA1c levels were measured at the Department of Clinical Chemistry, Karolinska University Hospital, Solna, Sweden. Analyses were performed on cryopreserved erythrocyte fraction measured by high performance liquid chromatography (Bio-Rad, Variant II); a method with total CVs of less than 5% within low and high HbA1c levels. HbA1c levels are expressed as monoS units (National Glycohemoglobin Standardization Program unit 9 0.9718-0.8925), as is used in clinical chemistry in Sweden. HbA1c levels were not measured in 32 case-control sets due to lack of erythrocytes in some samples. In all biochemical analyses, case-control sets were analysed in the same batch, and laboratory personnel were blinded to casecontrol status.
Intraclass correlations were previously calculated for two measurements of fasting levels of leptin and C-peptide in plasma and HbA1c in erythrocytes, from blood samples collected from 38 men with a 1-month interval [7] . Intraclass correlations were all higher than 0.90.
Statistical analyses
Wilcoxon signed-rank tests were used to test for differences in measured values between cases and controls. Marginal homogeneity test was used to test for case-control differences in BMI-distribution over three categories, and McNemar test was used to test for differences in the binary categorisation of HRT user/non-user. To assess crosssectional interrelationships between exposure variables, we used Spearman's partial correlation coefficients, adjusted for case-control status, age and fasting time.
Conditional logistic regression was used to calculate odds ratios (OR) as estimates of relative risk for breast cancer, and 95% confidence intervals (CI). All risk estimates were also assessed with adjustments for BMI (continuous) and HRT use. Number of births and age at first delivery were examined as potential confounders (data available for 84% of women), however the inclusion of these variables in the regression models did not appreciably change the risk estimates and thus were not retained in the models. The results from our study did not appreciably change when we performed a sensitivity analysis that excluded 95 cases diagnosed less than two years after study entry.
We stratified the analysis of breast cancer incidence by age at diagnosis (\55, C55 years; as a proxy for menopausal status at diagnosis), and by cases' tumour stage and ER/PR status at diagnosis. Results are not presented for the full study group because hormonal aetiological factors for breast cancer are known to differ among pre-and postmenopausal women [1] . Tumour stage is graded based on TNM status, and determines how far the tumour has progressed at diagnosis. We divided stage into the groups of stage I and stage II-IV. We also examined BMI as a possible effect modifier by performing unconditional regression analyses, adjusted for matching factors and HRT use, in groups of normal weight (BMI \25 kg/m 2 ) and overweight-obese (BMI C25 kg/m 2 ) women. Since nearly all variables in our study increased with age, age-specific cut-points were calculated within age categories \45, 45-\55, and C55 years and the same tertile cutpoints were used across subgroups. As C-peptide levels were significantly higher among non-fasting subjects, only case-control sets with the same fasting status (\4 h; C4 h since last meal) were included in analyses of C-peptide. Risk with BMI was also assessed using the World Health Organisation (WHO) categorisation: normal weight (BMI \25 kg/m 2 ), overweight (BMI 25-\30 kg/m 2 ) and obesity (BMI C30 kg/m 2 ). Linear trends in ORs were assessed by likelihood ratio tests, assigning an increasing score of 1, 2 and 3 to each increasing tertile level. Formal tests of heterogeneity between the ORs across tertiles in subgroups were based on v 2 statistics. Statistical analyses were performed using SAS (version 9.1, SAS Institute, Cary, NC) and STATA (version 9.2, StataCorp LP, College Station, Texas), and statistical significance was inferred at two-sided P \ 0.05.
Results
Baseline characteristics
Baseline characteristics of cases and matched controls are shown in Table 1 . Cases were more likely to be using HRT at baseline compared to controls (24.0 vs. 11.3%). The median BMI and the proportion of subjects who were overweight were not significantly different between cases and controls. Table 2 describes the characteristics of the breast cancer cases. Cases had a median age of 52.5 years at recruitment (40.4 years and 57.0 years in the VIP and MSP subcohorts, respectively), and the median time to diagnosis was 4.4 years (4.8 years and 4.3 years in the VIP and MSP subcohorts, respectively). ER and PR status was known for 495 (88.2%) women, of which the majority (62.4%) were ER+/PR+ status. Of the 561 cases, 263 (46.9%) were diagnosed as having a stage I tumour, 290 (51.7%) were classified as stage II-IV and 8 (1.4%) as unknown. Of women with known receptor status, the proportion of stage II-IV tumours that were ER+ (76%) or PR+ (61%) was slightly lower than the proportion of stage I tumours that were ER+ (84%) or PR+ (71%). Furthermore, women with a stage II-IV tumour were slightly younger at baseline (median 51.5 vs. 53.5 years).
BMI was strongly positively correlated with leptin (r = 0.72), and moderately correlated with C-peptide and HbA1c (Table 3) . Adiponectin was negatively correlated with BMI, leptin and C-peptide, and was weakly negatively correlated with HbA1c.
Stratification by age at diagnosis There was no significant association between BMI, leptin, adiponectin, C-peptide and risk of breast cancer when stratified by age at diagnosis (\55 or C55 years; Table 4 ). The associations with BMI remained non-significant when categorised according to the WHO criteria (data not shown). HbA1c analysed in tertiles was significantly inversely related to risk among women C55 years of age at diagnosis (OR for highest vs. lowest tertile = 0.61, 95% CI, 0.40-0.94, P trend = 0.02) whereas no association was found among women \55 years at diagnosis, however the differences were not statistically significant (P heterogeneity = 0.17). Results were similar when we stratified by \50, 50-60, [60 years at diagnosis, or by menopausal status at baseline, with essentially no differences between the groups.
Stratification by tumour stage
The associations of BMI, leptin and HbA1c with breast cancer risk differed significantly between the stage I diagnosed tumours and stage II-IV tumours (P heterogeneity all \0.05) ( Table 5 ). High levels of these factors were significantly (or borderline significantly) inversely associated with stage I disease, whereas higher levels of BMI and leptin were non-significantly related to an increased risk of stage II-IV disease. Obese women (WHO definition) were observed to have a decreased risk of breast cancer in the stage I group, whereas obesity was not related to risk in the stage II-IV group; adjusted ORs for obesity vs. normal weight were 0.45 (95% CI, 0.24-0.85) and 0.95 (95% CI, 0.55-1.64), respectively. In the stage II-IV group, high levels of HbA1c conferred an increased risk among overweight-obese women; OR for the highest vs. lowest tertile was 1.92 (95% CI, 1.00-3.68, P trend = 0.05), but not among women of normal weight; OR 0.62 (95% CI, 0.34-1.12, P trend = 0.13) (P heterogeneity = 0.02). BMI did not modify risk associations for any other risk factor than HbA1c.
There was no evidence that the associations differed significantly between the VIP and MSP cohorts. However, 
Stratification by ER/PR status
There were only minor differences overall in the exposure-risk associations according to ER+, ER-, PR+, or PR-status, or different ER/PR status combinations, and none of these differences were statistically significant (P heterogeneity all[0.05) (data not shown).
Discussion
The main finding in this prospective study is that the associations of BMI, leptin and HbA1c with breast cancer risk differed significantly according to whether the tumour was diagnosed as stage I or stage II-IV. Elevated levels of these factors were inversely associated with stage I breast cancer, but were generally related to an increased risk of stage II-IV disease. To our knowledge, no previous prospective study has reported breast cancer risk according to tumour stage at diagnosis for the exposures included in our study, except for BMI. Whilst the mechanisms underlying our observed strong decreased risks with stage I tumours are unclear, the suggestive positive association with stage II-IV tumours at diagnosis is supported by other epidemiological findings. Previous studies have reported that obesity in both pre-and post-menopausal women is associated with advanced disease at diagnosis, including large tumour size, high cellular proliferation and lymph node metastasis [4] . Increasing BMI is also significantly associated with higher rates of death due to breast cancer, compared with normalweight individuals [8] . Additionally, type 2 diabetes, a consequence of several years with insulin resistance and subsequent b-cell failure, is associated with increased tumour stage and size [9] , independent of BMI. Thus, there is growing evidence that a metabolic profile comprising overweight and insulin resistance is related to tumour progression. The biological mechanisms underlying this OR, odds ratio; CI, confidence interval; BMI, body mass index; HbA1c, glycated haemoglobin a Since nearly all variables in our study increased with age, tertile cut-points were calculated within baseline age categories \45, 45-\55, and C55 years, and the same tertile cut-points were used across subgroups. The cut-points for BMI were \22. Adjusted for BMI and HRT use. Leptin was not adjusted for BMI due to the high correlation (r = 0.72) with BMI. The BMI association was adjusted for HRT use only c Only case-control sets with the same fasting time before blood sampling were included in analyses of C-peptide relation are thought to involve (1) increased bioavailable oestrogen levels, (2) elevated insulin and insulin-like growth factor-1 (IGF-I) levels, and (3) the action of adipocyte-derived adipocytokines such as leptin (growthstimulating effects) and adiponectin (inhibitory effects) [10] [11] [12] [13] .
In our study, we observed a non-significant inverse association between C-peptide levels and (i) a younger age (\55 years) at diagnosis and (ii) risk of stage I tumours. Conversely, a non-significant positive association was observed with an older age (C55 years) at diagnosis, and risk of stage IV tumours. Although most [14] [15] [16] [17] [18] (but not all [19] ) case-control studies reported a positive relation between hyperinsulinaemia and breast cancer risk, most previous prospective studies showed no association with overall risk [20] [21] [22] [23] [24] [25] . However, when stratified by age or menopausal status, two prospective studies [24, 25] observed a similar difference in risk estimates to what we observed in our study. The mechanisms for a possible inverse association of BMI and insulin with breast cancer OR, odds ratio; CI, confidence interval; BMI, body mass index; HbA1c, glycated haemoglobin a Age-specific tertile cut-points of exposure factors were used, as described in Table 4 , footnote (a)
b Adjusted for BMI and HRT use. Leptin was not adjusted for BMI due to the high correlation (r = 0.72) with BMI. The BMI association was adjusted for HRT use only c Only case-control sets with the same fasting time before blood sampling were included in analyses of C-peptide diagnosis at a younger (premenopausal) age, or with early stage breast cancer, are unknown. Previous studies have demonstrated that high circulating IGF-I levels are associated with increased breast cancer risk in pre-but not postmenopausal women [26] . IGF-I has similar structural and functional features to insulin [27] and there is some evidence that IGF-I enhances insulin sensitivity and lowers blood glucose in insulin-resistant states [27, 28] . Possibly, an inverse association between C-peptide levels and breast cancer risk in some subgroups could be partly explained by these insulin-sensitising effects of IGF-I. A previous pooled analysis of prospective cohort studies has shown that obesity is associated with an increased breast cancer risk among postmenopausal women, but with a slight decreased risk among premenopausal women [1] . In our study there were no clear associations of BMI with breast cancer risk according to age at diagnosis, although our confidence intervals do include the pooled risk estimate values. Previous studies indicate that the BMI-risk association might be stronger among women older than 65 years [1, 2] , of which there were few women in our cohort. Our BMI risk estimates may also have been attenuated due to self-report height and weight measurements that were obtained for most women in the MSP cohort, which is likely to have led to underestimation of BMI values, particularly among overweight women [29] . Nevertheless, when we separately analysed women from the VIP cohort, who did have measured values of height and weight, our risk estimates according to age at diagnosis were similar to women with self-reported values. However, our results for BMI by tumour stage did appear slightly stronger in the VIP cohort.
Previous epidemiological studies of leptin and breast cancer risk have observed no association [30, 31] , or a weak inverse association among premenopausal women [32] . In our study, no risk-difference was found between the groups based on age at diagnosis. Contrary to other epidemiological studies [33] [34] [35] [36] , and the reported insulinsensitising, anti-proliferative and apoptotic activity of adiponectin [10, 11, 13 , 37], we did not observe a statistically significant inverse association between adiponectin levels and breast cancer risk in this study.
HbA1c reflects the average plasma glucose concentration over the preceding 6-8 weeks, and is considered a marker for impaired glucose metabolism [38] . Our findings for HbA1c are consistent with the only other prospective cohort study [39] that we know of, that has examined the association of HbA1c with breast cancer risk. Lin et al. [39] showed an inverse association of HbA1c with breast cancer among postmenopausal women, and no association among premenopausal women, which was similar to our results stratified by age at diagnosis. Whilst Lin and colleagues did not examine the effects of HbA1c by tumour stage, they did observe an inverse association with well differentiated (low-grade) tumours and no association with poorly differentiated tumours [39] . In our study, HbA1c levels were significantly inversely associated with risk of stage I breast tumours, but were unrelated to stage II-IV tumours except when further stratified by BMI categories, where we observed a two-fold higher association for overweight women. It is possible that overweight may potentiate the effects of HbA1c in the same way that leptin, oestrogen, insulin and other mitogenic factors can act synergistically to increase proliferation and progression of breast tumour cells [10, 39, 40] . Other prospective studies have used alternate measures of glucose metabolism including fasting or post-load glucose, but have shown inconsistent results with breast cancer risk [21, 22, 41, 42] .
Although it has been suggested that the aetiology of breast cancer may depend on its ER and PR status [3, 43] , we found no evidence for effect modification by ER/PR status in our study. MacInnis et al. [2] also reported no overall differences in the association of body size measures and breast cancer risk according to ER/PR status, however among women at least 15 years post-menopause, body size measures were positively associated with ER+ tumours and weakly negatively associated with ER-tumours.
This study has several strengths, including the prospective, population-based study design and almost 100% complete coverage of incident cancers from the cancer registry. Another strength of our study is that we examined several factors related to overweight and insulin resistance. We had a relatively large sample size, however larger samples will be required to conclusively elucidate the associations by stage and other tumour characteristics, and within smaller subgroups such as premenopausal women, and by HRT use.
Only one blood sample was taken, which may not represent an individual's long-term exposure levels, however, we previously observed high intraclass correlations (r [ 0.90) for measurements of fasting C-peptide, leptin and HbA1c in blood samples collected 1 month apart [7] , suggesting that a single measurement accurately reflects at least short-term average levels. One of the limitations of our study is the difficulty in exploring whether some of our results were driven by differences in age, cohort, fasting time or tumour stage, since in our study these factors were related, e.g. older participants were more likely to be recruited from the MSP, have non-fasting measures, and were slightly more likely to be diagnosed with a stage I tumour. Although we were able to match or adjust for these factors, we could not examine their individual effects simultaneously. We tried to minimise the possibility of detection bias (i.e. that women having regular mammography would be more likely to be diagnosed with an earlystage cancer) by excluding all cases from the screening cohort with a time to diagnosis less than 6-months after baseline, and our results did not appreciably change when we excluded cases diagnosed less than two years after baseline. Another limitation was the lack of information on menopausal status at the time of cancer diagnosis, thus we used age as a proxy measure.
In conclusion, we found that several markers of overweight and insulin resistance, including BMI, leptin and HbA1c, may influence breast tumour initiation and progression.
